

Inspired by

the sea

Driven by

science

Motivated by

people



A vibrant underwater scene featuring a diverse coral reef. On the left, there are large, bushy orange and yellow corals. In the center, a delicate, feathery black coral stands out. To the right, a large, intricate red branching coral dominates the foreground. Several small, colorful fish are visible swimming in the clear blue water.

**Leading company
in the discovery,
development, and
commercialization of
marine-based oncology
treatments.**

PharmaMar is one of the European groups that invests the most in Research and Development in proportion to sales.



PharmaMar is a global biopharmaceutical company that, since its founding in 1986, has focused on innovative research and development (R&D) aimed at improving the health of patients with severe diseases.

PharmaMar's therapeutic platform is the sea, which we consider holds untapped therapeutic potential. To validate this theory, PharmaMar has invested over 1 billion euros in R&D since its inception. This approach is now bearing its fruit.

PharmaMar has three drugs approved by various regulatory agencies for four indications: Soft Tissue Sarcoma,

Ovarian Cancer (trabectedin), Multiple Myeloma (plitidepsin), and Small-Cell Lung Cancer (SCLC) (lurbinectedin).

PharmaMar has achieved a success rate of 37% in its research, compared to the industry average of 10.8%, as three out of eight compounds that have undergone clinical trials have been approved.

Since our inception, we have treated more than 150,000 patients with our drugs and constantly strive to make them accessible to all affected individuals globally.

PharmaMar is firmly committed to seeking innovative treatments for rare diseases. It currently holds 22 orphan drug designations worldwide.

PharmaMar has also a subsidiary, Sylentis, which focuses on researching therapeutic applications of gene silencing (RNAi interference).

Global Trends in R&D 2024: Activity, productivity, and enablers. (s. f.). IQVIA.

<https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2024-activity-productivity-and-enablers>

First Spanish company to obtain “Accelerated approval” from the FDA.

The sea as a therapeutic platform

Considering that terrestrial nature has historically provided excellent medicines, like penicillin and salicylic acid, and that the sea covers three-quarters of our planet and is home to 80% of living organisms, PharmaMar hypothesized that the sea might harbor valuable treatment options for diseases such as cancer.

Our focus has primarily been on studying marine invertebrates. These organisms, lacking immune systems and unable to flee, have developed complex defense mechanisms over the course of evolution, making them a valuable source of bioactive compounds with therapeutic potential.

PharmaMar's oncological research process begins at sea with marine expeditions and covers the entire drug development chain until it reaches patients, encompassing the following stages.



As a result of this research process, PharmaMar has a portfolio of products in various stages of clinical development.



First:

Our drug development process begins with marine expeditions conducted worldwide by a team of professional divers and marine biologists to collect samples.

We have over 400,000 marine samples, the world's largest collection. Besides our advances in cancer treatment, we have contributed to the knowledge of the marine environment and its biodiversity by discovering new species.



After:

A first taxonomy is conducted during the marine expeditions. Once the marine samples arrive at our laboratory in Madrid, Spain, the extracts are analyzed for antitumor activity against a panel of tumor cells. Those that show activity are fractionated and purified to isolate the active principle responsible for the activity and chemical processes are designed to produce synthetic compounds in sufficient quantities to continue the research process.



Then:

Once the synthesis is obtained, possible formulations are considered to determine their activity against various tumours and their safety profile, the purpose of the entire preclinical phase is to generate information on which to base clinical research.

Once both preclinical and clinical trials are completed, the Company submits the registration dossier to the different regulatory agencies for review and authorization for commercialization.

From seaside to bedside

Expeditions & Collection

Leading marine expeditions around the world

More than 400,000 marine samples, the world's largest collection

Over 200 expeditions in 35 countries worldwide



Cell Biology & Chemistry & Preclinical Research

Screening and detection of antitumor activity

Molecule synthesis and optimization

Patent protection

Preclinical studies

Pharmaceutical Development & Operations

Factory audited by the FDA, EMA and PMDA

GMP Production*

Drug candidates

Potential ADCs*



*

Regular inspections by Health Authorities (EMA, FDA, PMDA, among others)

GMP: Good Manufacturing Practices

ADC: Antibody-Drug Conjugate



Clinical & Regulatory

Clinical trials

Postmarketing studies

Registration dossier to the different regulatory agencies



Commercial



Own commercial network in the EU

Licenses & agreements with experienced companies





From seaside to bedside

PharmaMar conducts basic research with marine expeditions, compound isolation, chemical synthesis, in vivo and in vitro studies to discover and develop new antitumor compounds of marine origin.

The marine expeditions are in accordance with all laws and ecological regulations of various governments, non-governmental organisations (NGOs) and others, and our extraction process involves extremely small sample sizes harvested by hand.

PharmaMar's Expanding Oncological Research

Our purpose is to improve the healthcare outcomes of patients afflicted by serious diseases through our innovative medicines.

PharmaMar is actively advancing the field of oncology with several trials in various phases and stages, targeting multiple cancer types with a diverse range of molecules.

We are continually preparing new candidates for clinical development and advancing preclinical trials to bring innovative molecules into our clinical pipeline. PharmaMar remains dedicated to pushing the boundaries of cancer research and delivering new hope to patients worldwide.

Our commitment to innovation drives us to explore and develop groundbreaking therapies that address unmet medical needs in oncology. Through this unwavering dedication, we strive to make a meaningful impact on the future of cancer care.





A global company

The pioneer company in the world to cover all phases of development of a marine-derived antitumor drug through to its commercialization.

With headquarters in Madrid (Colmenar Viejo), we have subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland, and the United States. Our drugs reach over 70 countries.




In Europe, our proprietary commercial network ensures efficient distribution and effective marketing of our products.

Where we do not have our own subsidiaries, our policy is to enter agreements with strategic local partners to market our therapies and ensure we reach all the patients who need them. We have 19 global partners, including Jazz Pharmaceuticals, Janssen, and Luye Pharma Group, among others.



Our facilities

PharmaMar has more than **3,800 m²** of production warehouse in Madrid, where its treatments are manufactured and stored. This space is specially designed to meet the highest GMP (Good Manufacturing Practices) standards.



Production facilities

- 17,000 m² plant in Madrid
- 4,200 m² R&D laboratories
- 3,800 m² built according to GMP standards
- EMA, FDA, PMDA, MFDS among others approval
- API manufacturer, secondary packaging, and final product release worldwide.



Our team

We are a multidisciplinary team consisting of biologists, chemists, physicians, engineers, IT specialists, laboratory technicians and biostatistical experts, among others, that work tirelessly to make our goal a reality: **improving the health of patients affected by serious diseases.**

Our Clinical, Medical Affairs, Regulatory Affairs, R&D and Manufacturing departments are supported by an unparalleled team of legal, logistical, financial, administrative and commercial experts, enabling our research to be available to patients in need.



15
nationalities



65%
are university
graduates



20%
have earned
PhDs



61,5%
are females



Avenida de los Reyes, 1
Polígono Industrial La Mina
28770 Colmenar Viejo,
Madrid, Spain

Phone: +34 91 846 60 00

Fax: +34 91 846 60 01



pharmamar.com



Pharma
Mar

The logo graphic consists of three parallel, slanted rectangular bars of increasing length, stacked vertically, creating a sense of motion or a stylized 'M'.